A randomised Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.

BI 456906 showed no unexpected tolerability concerns and reduced placebo-corrected bodyweight by up to 12.37% in Japanese men with overweight/obesity after 16 weeks' treatment. This article is protected by copyright. All rights reserved.